Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on to drop a secondary because a boxed-warning proposal from the review division put 505(b)(2) literature-to-product bridge table in play. Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on to drop a secondary because a boxed-warning proposal from the review division put 505(b)(2) literature-to-product bridge table in play; CMC change-control owner should say what 505(b)(2) literature-to-product bridge table proves for Pharma & Life Sciences.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. CMC change-control owner can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to drop a secondary. 4. Two facts in 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division conflict for CMC change-control owner; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim CMC change-control owner would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.